The United States StuDy for EvalUating EndovasculaR TreAtments of Lesions in the Superficial Femoral Artery and Proximal Popliteal By usIng the Protege EverfLex NitInol STent SYstem II (DURABILITY II)

University of Wisconsin School of Medicine and Public Health, Madison, Wisc. Electronic address: .
Journal of vascular surgery: official publication, the Society for Vascular Surgery [and] International Society for Cardiovascular Surgery, North American Chapter (Impact Factor: 3.02). 05/2013; 58(1). DOI: 10.1016/j.jvs.2012.12.066
Source: PubMed


Angioplasty and stenting are options for revascularization of symptomatic femoral popliteal disease. Although angioplasty alone is effective in short lesions, longer lesions are often treated with stents. Multiple overlapping stents are expensive and may be associated with stent fracture. This trial evaluated the safety and efficacy of a single self-expanding stent up to 20 cm in length in patients with atherosclerotic disease of the superficial femoral artery (SFA) and proximal popliteal artery.

Patients with lesions >4 cm and <18 cm were enrolled in this nonrandomized, prospective, multicenter trial that evaluated the Protégé EverFlex Self-Expanding Peripheral Stent System (Covidien, Plymouth, Minn). The study's primary end points were the 30-day major adverse event rate and duplex ultrasound-assessed patency at 1 year. These were compared with published performance goals. A preplanned analysis was conducted for the primary effectiveness end points at 1 year. Follow-up, including history, ankle-brachial index, patient-reported outcomes, duplex ultrasound assessment, and radiographs, is planned through 3 years. There was core laboratory review of angiograms, ultrasound scans, and plain radiographs. A subgroup of patients was studied with graded treadmill testing.

The study enrolled 287 patients (66% male; mean age, 68 years) with stenotic, restenotic, or occluded lesions of the SFA at 44 investigational sites in the United States and Europe. Systemic comorbidities included hypertension (88%), hyperlipidemia (86%), diabetes (43%), and prior SFA intervention (41%). The mean lesion length measured by the core laboratory was 89 mm. The mean normal-to-normal lesion length measured by sites was 110 mm. A total of 303 stents were implanted, and 95% of patients received a single stent. No major adverse events occurred at 30 days. At 1 year, primary outcome of duplex ultrasound stent patency was 67.7% in evaluable patients, and among 1-year secondary outcomes, the mean ankle-brachial index increased by 0.25. Walking Improvement Questionnaire scores improved in pain by 33.7, distance by 37.1, speed by 18.6, and stair climbing by 24.7. The Kaplan-Meier estimate of primary patency was 77.2%, primary assisted patency was 86.9%, and secondary patency was 87.3%. Rutherford clinical category improved in 83.5% of patients. Stent fracture rate was 0.4%. Matched absolute claudication distance was 412 feet greater and was not statistically different in this subgroup of 29 individuals.

The results of DURABILITY II (StuDy for EvalUating EndovasculaR TreAtments of Lesions in the Superficial Femoral Artery and Proximal Popliteal By usIng the Protégé EverfLex NitInol Stent SYstem II) suggest that a new single stent strategy is safe and effective for the treatment of long lesions of the SFA and proximal popliteal arteries at 1 year.

Full-text preview

Available from:
  • Source
    • "These data have led to US Food and Drug Administration (FDA) approval of a number of newer available stents that may provide greater flexibility, less stent fracture, and, possibly, more durable results. The Everflex Protégé (Covidien, Mansfield, MA, USA) nitinol self-expanding stent was evaluated in The United States Study for Evaluating Endovascular Treatments of Lesions in the Superficial Femoral Artery and Proximal Popliteal By using the Protégé Everflex Nitinol Stent System (DURABILITY I and DURABILITY II) trials.30,31 Although these trials were nonrandomized, they enrolled a similar group of patients evaluated in previous randomized studies and treated long complex lesions (mean lesion lengths of 96.4±26.8 and 89±44.8, "
    [Show abstract] [Hide abstract]
    ABSTRACT: The endovascular management of obstructive disease of the superficial femoral artery (SFA) is challenging due to unique anatomical and biomechanical forces. Obstructive lesions of the SFA make up the largest proportion of lesions leading to symptomatic peripheral arterial disease. Accordingly, endovascular treatment of SFA disease is becoming increasingly common and, in many cases, is the preferred initial therapy. The use of self-expanding nitinol stents have proven superior to percutaneous transluminal balloon angioplasty in the treatment of intermediate length SFA stenosis. However, achieving durable results, as well as attaining adequate therapy for long occlusions typically seen in clinical practice, remains problematic. Newer technologies, such as paclitaxel eluting stents, seem promising in improving outcomes.
    Medical Devices: Evidence and Research 05/2014; 7(1):149-156. DOI:10.2147/MDER.S45472
  • [Show abstract] [Hide abstract]
    ABSTRACT: Trotz initial guter Erfolge nach Angioplastie bei peripherer arterieller Verschlusskrankheit (pAVK) bilden Restenosen das Hauptproblem. Sie werden durch neointimale Hyperplasie verursacht und können mithilfe antiproliferativer Substanzen effektiv unterdrückt werden. Zur längerfristigen Hemmung werden medikamentenbeschichtete Ballonkatheter (,,drug-coated balloon“, DCB) und -“drug-coated stents“ (DCS) eingesetzt.Die vorliegende Arbeit gibt einen Überblick über die DCB-Entwicklung, die aktuell eingesetzten Systeme und die vorliegenden klinischen Studien. Die Evidenz in der Behandlung der femoropoplitealen Arterien wird diskutiert.Es wurde eine systematische elektronische Literaturrecherche in Datenbanken medizinischer Fachzeitschriften, international registrierter klinischer Studien und publizierter Kongressbeiträge zum DCB-Einsatz im infrainguinalen Bereich im Zeitraum 2008 bis Juli 2013 durchgeführt.Hauptvorteile der DCB sind, dass kein Metall im Gefäß zurückbleibt, die unmittelbare Freisetzung hoher Substanzkonzentrationen und ihre Einsetzbarkeit in Bereichen, in denen DCS bisher kontraindiziert sind. Die klinische Evidenz der ,,paclitaxel drug-coated balloon“ (PTX-DCB) der 1. Generation wurde in verschiedenen kontrollierten randomisierten Studien aufgezeigt.In Abhängigkeit von der Läsionsart und dem Läsionsort sind DCB geeignet bei In-Stent-Restenosen, Restenosen oder in Bereichen der A. poplitea oder bei Seitenästen der A. profunda, in denen eine Stent-Applikation kontraindiziert ist.
    Gefässchirurgie 10/2013; 18(6). DOI:10.1007/s00772-013-1226-5 · 0.24 Impact Factor

  • Journal of Endovascular Therapy 12/2013; 20(6):767-9. DOI:10.1583/13-4430C.1 · 3.35 Impact Factor
Show more